Table 1 Results from full-text articles
Date | Study | Context | L | N | Age | Type | Stage | Uniqueness of study | Findings |
|---|---|---|---|---|---|---|---|---|---|
Jan 2004 | Extermann M et al.[12] | Single center pilot study assessing role of CGA in oncological treatment. | 3 | 15 | ≥70 | Breast | 55% Stage I, 45% Stage II | QOL was measured by the Functional Assessment of Cancer Treatment-Breast tool. Functional status was assessed by ADL, IADL, ECOG-PS, GDS, MNA, Charlson Comorbidity Index, CIRS-G. | CGA with follow-up can extend quality of life in these patients from treatment and prognostic aspects. |
Nov 2005 | Hurria A et al.[13] | Feasibility study concerning a cancer-specific CGA. | 3 | 43 | ≥65 | 25% breast, 18% CRC, 38% lung, 20% lymphoma | 5% Stage 1, 10% Stage II, 18% Stage III, 68% Stage IV | Specifies use of ADL, IADL, KPS, Timed Up and Go, BOMC, HADS, MOS, Seeman and Berkman Social Ties, BMI, % unintentional weight loss in the last six months in a CGA that is specific for cancer. Specifies ethnicity of participants as 90% white, 10% black. | The cancer-specific CGA can be completed by the majority of patients to provide reliable and valid results. |
Dec 2006 | Pope, D et al.[14] | Study of Geriatric Assessment in older patients with operable cancer. | 3 | 460 | >70 | 216 breast, 146 GIT, 71 GUT, 27 other | For breast cancer: 48% Stage 1, 39.3% Stage 2, 12.7% Stage 3. | Specified use of PACE, an advanced form of CGA using BFI, ECOG-PS, IADL, GDS, MMSE, ASA and SIC. | Geriatric Assessments can be a useful tool in evaluating fitness for surgery in the older cancer patient. |
Jan 2008 | Albrand, G and Terret, C [15] | Single-center review of assessment of breast cancer in the older. | 3 | 76 | >70 | Breast | Primary | Specific for breast cancer. Specifies use of CIRS-G score as part of CGA. | CGA should be performed before any treatment decisions are made. More trials need to be conducted involving older patients, to determine efficacy of chemotherapy in older breast cancer patients. |
March 2010 | Gironés, R et al.[16] | Single-center experience of use of CGA for breast cancer patients. | 3 | 91 | >70 | Breast | 26% Stage I, 58% Stage II, 16% Stage III | Specific for breast cancer, specifying use of ADL, IADL, ECOG PS, GDS, Charlson comorbidity index, BMI, Balducci criteria for frailty in CGA. | Function and independence in older breast cancer patients with co-morbidities can be preserved by use of CGA. CGA is often too time consuming to be practically assessed in an oncology setting. |
Jul 2010 | Molina- Garrido, M and Guillén-Ponce, C [17] | Single center comparison of two frailty screening tools and CGA. | 3 | 41 | ≥65 | Breast | 53.7% Stage I, 41.5% Stage II, 2.4% Stage III, 2.4% Stage IV | Specific for breast cancer. Specifies use of ADL, IADL, Charlson comorbidity index, Pfeiffer test for cognition and NSI. | Patients who had a score indicative of frailty had scores in CGA suggesting poorer physical function, malnutrition and cognition. |
Jul 2011 | Barthélémy, P et al.[18] | Single center retrospective review of recommendation of adjuvant chemotherapy to older breast cancer patients | 3 | 192 | >70 | Breast | Primary | Specific for primary breast cancer only. Specifies use of ADL, IADL, ECOG PS, GDS, BMI, MNA, CIRS-G. | Some components of CGA may be able to determine its use in predictability of chemotherapy use. |
Jul 2011 | Lazarovici, C et al.[19] | Single center investigation into what components of CGA correlate to need for geriatric referral within older cancer patients | 3 | 65 | ≥71 | Breast (29%), lung (24.6%), colorectal (7.6%) | 60% had metastatic disease | Specifies use of ADL, IADL, MMSE, BMI, CIRS-G | Patients who had CGA before they had made their cancer treatment decision were more likely to receive an altered treatment plan. |
Aug 2011 | Hurria, A et al.[20] | A multicenter trial to assess use of CGA in determining chemotherapy toxicity in older cancer patients | 3 | 700 | ≥65 | Lung (29%), GI (27%), gynaecological (17%), breast (11%), genitourinary (10%), or other (6%) | 5% Stage I, 12% Stage II, 22% Stage III, 61% Stage IV | Same CGA format used in previous study by Hurria et al.[13] | Some components of the CGA can be used to assess potential toxicity of chemotherapy in this group of older cancer patients. |